Guidant tests intravascular radiotherapy in Japan:
This article was originally published in Clinica
Guidant claims it has become the first to begin a clinical trial of intravascular radiotherapy in Japan. The Indianapolis, Indiana firm will assess its Galileo intravascular radiotherapy system as a treatment for in-stent restenosis in 75 patients at five Japanese sites. The Galileo system was first CE-marked for sale in Europe last year. Guidant recently gained European approval to sell the device as a treatment for long coronary lesions - as long as 47mm.
You may also be interested in...
Topline results with AZD1222 have shown a lower efficacy rate than the Pfizer and Moderna vaccines, but a subgroup receiving a half-dose in their first injection showed a 90% efficacy result.
Krka’s bottom line continues to be stronger than usual, driven by a hike in sales and leaner cost base. Looking to 2021, however, management brought investors back down to earth.
The COVID-19 pandemic has triggered extraordinary levels of collaboration. But competition remains, and many newly created coalitions have yet to be stress tested.